Pediatric Malignant Bone Tumors: A Review and Update on Current Challenges, and Emerging Drug Targets

Twana M Jackson; Mark Bittman; Linda Granowetter

doi:10.1016/j.cppeds.2016.04.002

Pediatric Malignant Bone Tumors: A Review and Update on Current Challenges, and Emerging Drug Targets

Curr Probl Pediatr Adolesc Health Care. 2016 Jul;46(7):213-228. doi: 10.1016/j.cppeds.2016.04.002. Epub 2016 Jun 2.

Authors

Twana M Jackson¹, Mark Bittman², Linda Granowetter³

Affiliations

¹ Division of Pediatric Hematology Oncology, NYU Langone Medical Center, New York, NY. Electronic address: Twana.Jackson@nyumc.org.
² Department of Radiology, NYU Langone Medical Center, New York, NY.
³ Division of Pediatric Hematology Oncology, NYU Langone Medical Center, New York, NY.

PMID: 27265835
DOI: 10.1016/j.cppeds.2016.04.002

Abstract

Osteosarcoma (OS) and the Ewing sarcoma family of tumors (ESFT) are the most common malignant bone tumors in children and adolescents. While significant improvements in survival have been seen in other pediatric malignancies the treatment and prognosis for pediatric bone tumors has remained unchanged for the past 3 decades. This review and update of pediatric malignant bone tumors will provide a general overview of osteosarcoma and the Ewing sarcoma family of tumors, discuss bone tumor genomics, current challenges, and emerging drug targets.

Publication types

Review

MeSH terms

Biopsy
Bone Neoplasms / diagnostic imaging*
Bone Neoplasms / etiology
Bone Neoplasms / genetics
Bone Neoplasms / therapy*
Bone and Bones / pathology
Child
Genetic Predisposition to Disease
Humans
Magnetic Resonance Imaging
Molecular Targeted Therapy / methods
Osteosarcoma / diagnostic imaging*
Osteosarcoma / etiology
Osteosarcoma / genetics
Osteosarcoma / therapy*
Prognosis
Radiography
Risk Factors
Sarcoma, Ewing / diagnostic imaging
Sarcoma, Ewing / etiology
Sarcoma, Ewing / genetics
Sarcoma, Ewing / therapy